Standing on the shoulders of the significant body of research on Alpha-1 Antitrypsin Deficiency sponsored by the Alpha-1 Foundation, Inc., and others, TAP will directly fund drug therapy and device projects within pharmaceutical or biotech companies that show significant promise in helping people with liver disease and COPD caused by Alpha-1 Antitrypsin Deficiency.

Making a Difference Today

TAP is singularly focused on making a positive difference in the lives of people suffering from liver disease or COPD caused by Alpha-1. Of the twelve therapeutic development programs we’ve funded, five are in active clinical trials as of Fall 2022, and another is in the pre-clinical stage.

Part of what makes us unique is our focused approach. This focus allows TAP to keep administrative costs to a minimum and to put more of our resources directly to work developing cures and therapies.

Contact TAP today to see how we are making a difference!

THE ALPHA-1 PROJECT®
For more information about how we are fighting to eliminate the effects of liver disease and COPD caused by Alpha-1 Antitrypsin Deficiency, contact us:

3300 Ponce de Leon Blvd.
Coral Gables, FL 33134
Phone: 305-648-9541
Toll-free: 888-920-0002
Fax: 786-513-0980
E-mail: info@alpha1.org

Or visit us on the Web at www.a1f.org/thealpha1project
What is Alpha-1?

Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic condition that causes the liver to retain alpha-1 antitrypsin. Alpha-1 antitrypsin is an essential protein produced by the liver that blocks certain proteases in the blood from causing damage to otherwise healthy elastic tissue. People with the condition Alpha-1 have a build-up of the alpha-1 antitrypsin protein in the liver, causing scarring of the liver and a deficiency of alpha-1 antitrypsin throughout the rest of the body. The resulting low levels of alpha-1 antitrypsin in the bloodstream allow certain proteases to go unchecked causing uninhibited destruction of elastic fibers like those found in the lungs. The common results of Alpha-1 are liver failure in young people and liver disease and/or chronic obstructive pulmonary disease (COPD) in adults.

There are fewer than 10,000 confirmed cases of Alpha-1 in the U.S. However, it is believed that widespread testing would reveal that more than 100,000 people actually have Alpha-1.

The Alpha-1 Project Difference

The Alpha-1 Project (TAP) is uniquely qualified to support new drug discovery and development in Alpha-1. TAP directly invests in and supports pharmaceutical and biotech companies with highly promising compounds and devices that have the ability to eradicate the effects of liver disease and COPD caused by Alpha-1. This funding helps bridge the gap between basic academic research and the development of new drug targets and devices to find therapies and cures for Alpha-1. TAP leverages its investments by inviting pharmaceutical and biotech companies to participate in its projects. The resulting catalytic capital helps get these promising therapies and devices through clinical trials and into commercialization.

Our investment agenda for TAP is driven by members of our Scientific and Business Advisory Council and has focused on highly promising therapies that need additional funding and support to complete clinical trials. To date, TAP has Invested in 12 therapies directly targeting Alpha-1, and 4 tools that assist in the therapeutic development process.

What is TAP?

TAP is a wholly-owned subsidiary of the Alpha-1 Foundation, Inc., singularly focused on investing in highly promising drug therapies and devices that can eliminate the effects of liver disease and COPD caused by Alpha-1 Antitrypsin Deficiency. The actions of TAP are guided by its vision.

To create a world without the effects of COPD and liver disease caused by Alpha-1 Antitrypsin Deficiency.

Building Upon the Success of the Alpha-1 Foundation

The Mission Statement of TAP highlights its unique, cooperative and comprehensive approach to finding a cure.